BioWorld

April 3, 2002

Kalypsys Raises $43M In First Round, Plans Platform Growth

Kalypsys Inc. raised $43 million in its first round of financing and will now look to grow the technology that gave it its start. (BioWorld Today) Read More

Microbia Gets $26M In Series C To Fund Anti-Infective Drugs

Maternal Autoantibodies Confer Type I Diabetes On Transgenic, Disease-Modeling NOD Embryo

Ambit Enters Collaboration With AstraZeneca On Protein Targets

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...